Book Value per Share: Enanta Pharmaceuticals (ENTA)

Enanta Pharmaceuticals leverages its own R&D base to create a biopharmaceutical environment for combating viruses and integrates its patents into global distribution networks through B2B partnerships. Enanta Pharmaceuticals combines its scientific potential with global leaders to seek therapies for COVID-19 and hepatitis. The current figure is 3.44. This price chart reflects the impact of reduced licensing payments and clinical trial costs.

Enanta Pharmaceuticals Inc. (ENTA): Share Book Value from 07/04/2022 to 10/28/2026

enanta.com - analytical breakdowns and key metrics (ENTA)

- price and consensus price forecast:

Stock Quotes Enanta|ENTA - Analyst Forecast Prices

- market capitalization data:

Market Capitalization Enanta Pharmaceuticals, Inc.|ENTA - Enterprise Value

- book capitalization data:

Net Assets per Single Share Enanta Pharmaceuticals|ENTA - Net Asset Value|Market Capitalization to Book Value Ratio enanta.com|ENTA - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Capital Enanta Pharmaceuticals|ENTA - Long-Term Debt to Capital|Short-Term Debt to Equity Enanta Pharmaceuticals, Inc.|ENTA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Enanta Pharmaceuticals, Inc.

Fundamental company valuation:Enanta - ENTA

Manufactured products of Enanta Pharmaceuticals, Inc.

Book value per share is calculated as the ratio of equity to the number of issued shares, determining the asset's intrinsic value regardless of market fluctuations. The trend in book value per share reflects the capitalization of Enanta Pharmaceuticals (ENTA) scientific achievements within alliances for the treatment of COVID-19 and hepatitis, allowing investors to assess the company's actual margin of safety.

Competitors of Enanta Pharmaceuticals (ENTA)

Accounting Value per Share Gilead Sciences Inc GILD|CDTX - Book Price of a Share|NVAX: Book Value per Share|CVAC (curevac.com) - Book Value per Share|Net Assets per Single Share Valneva VALN|Share Book Value Vir Biotechnology Inc|SIGA Corp (SIGA) - Book Value per Share|Accounting Value of a Share Emergent Bio (EBS)|Book Value per Share AVIR (Atea Pharmaceuticals)|Invivyd Inc - Book Value per Share|Net Assets per Single Share Inovio (INO)|HLVX: Accounting Value of a Share|KLRS (Kalaris Therapeutics, Inc.) - Net Assets per Single Share|Dyadic International, Inc. (DYAI) - Accounting Value per Share|NNVC (NanoViricides Inc.) - Book Value per Share|Book Value per Share talphera.com (TLPH)|Cocrystal Pharma (COCP) - Accounting Value per Share|Accounting Value of a Share trawspharma.com TRAW|Accounting Value per Share Dogwood Therapeutics DWTX|Net Assets per Single Share Qualigen Corp QLGN|Book Value per Share ALVR (AlloVir Bio)|VBIV: Net Assets per Share|Net Assets per Single Share virios.com VIRI|Accounting Value of a Share Vaxart